Dermata Therapeutics, Inc.
DRMA
$1.21
-$0.02-1.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 142.53% | 45.72% | 36.32% | 52.41% | 32.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.00% | -17.67% | -40.62% | -45.42% | -38.53% |
| Operating Income | -70.00% | 17.67% | 40.62% | 45.42% | 38.53% |
| Income Before Tax | -74.42% | 19.79% | 40.91% | 46.68% | 39.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.42% | 19.79% | 40.91% | 46.68% | 39.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.42% | 19.79% | 40.91% | 46.68% | 39.87% |
| EBIT | -70.00% | 17.67% | 40.62% | 45.42% | 38.53% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 55.49% | 89.29% | 82.04% | 91.92% | 96.04% |
| Normalized Basic EPS | 55.48% | 89.28% | 82.04% | 91.92% | 96.04% |
| EPS Diluted | 55.49% | 89.29% | 82.04% | 91.92% | 96.04% |
| Normalized Diluted EPS | 55.48% | 89.28% | 82.04% | 91.92% | 96.04% |
| Average Basic Shares Outstanding | 291.83% | 648.57% | 228.98% | 560.13% | 1,416.25% |
| Average Diluted Shares Outstanding | 291.83% | 648.57% | 228.98% | 560.13% | 1,416.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |